乳腺癌大分割区域淋巴结照射患者的剂量学与毒性结局:限制放射性肺炎风险的最佳剂量体积限值是什么
该研究回顾性分析了2018年9月至2021年12月在匹兹堡大学医学中心接受大分割区域淋巴结照射(40-43 Gy/15-16次)的191例乳腺癌患者,中位随访20.3个月。全队列急性1级肺炎发生率为6.8%,慢性1级肺炎为29.8%,无急性3级及以上或慢性2级及以上肺炎。作者认为肺V20Gy<26%在该队列中似乎安全,但需更大队列数据评估剂量学预测因素和安全上限。
要点
- 全队列急性1级肺炎发生率为6.8%(13/191),仅1例发生急性2级肺炎。
- 慢性1级肺炎发生率为29.8%(57/191),无慢性2级及以上肺炎。
- 作者认为肺V20Gy<26%在该队列中似乎安全,但并非安全上限。
核心结论
- 在该接受大分割区域淋巴结照射的乳腺癌队列中,症状性肺炎发生率低,即使整合了HER2/neu靶向治疗、化疗、激素治疗及内乳淋巴结照射。
- 肺V20Gy<26%在该队列中似乎安全以限制症状性肺炎,但这并不代表安全上限。
- 鉴于症状性肺炎事件率低,需要更大队列数据来评估剂量学预测因素和肺剂量安全上限。
研究设计与样本
- 回顾性综述2018年9月至2021年12月在匹兹堡大学医学中心接受肿块切除或乳房切除术后大分割区域淋巴结照射(40-43 Gy/15-16次)的所有乳腺癌患者,收集剂量学和结局数据。
- 所有放疗后胸部计算机断层扫描(CT)由人工审阅,以评估急性(放疗后≤6个月)或慢性(放疗后>6个月)肺炎的证据。
- 共191例患者符合条件,中位随访20.3个月(范围5.1-42.2个月)。
主要发现
- 全队列急性1级肺炎发生率为6.8%(13/191),在放疗后≤6个月接受胸部CT的患者中为39.4%(13/33)。
- 仅1例患者发生急性2级肺炎。
- 全队列慢性1级肺炎发生率为29.8%(57/191),在放疗后>6个月接受胸部CT的患者中为77%(57/74)。
- 无患者发生急性3级及以上或慢性2级及以上肺炎。
关键数值与推荐
- 进行中的RT CHARM试验将同侧肺接受≥18 Gy的体积百分比限制在35%至40%。
- 作者认为肺V20Gy<26%在该队列中似乎安全以限制症状性肺炎,但并非安全上限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although published data have supported the use of hypofractionated regional nodal irradiation (HF-RNI) for breast cancer, limited dosimetric data exist to evaluate predictors of lung toxicity. The ongoing RT CHARM trial limits the percentage of ipsilateral lung volume that receives ≥18 Gy to 35 to 40%. We assessed dosimetry, toxicity, and disease outcomes in patients with breast cancer treated with HF-RNI with a particular focus on pneumonitis. METHODS AND MATERIALS: We retrospectively reviewed all patients with breast cancer treated with HF-RNI (40-43 Gy in 15-16 fractions) after either lumpectomy or mastectomy at The University of Pittsburgh Medical Center from September 2018 to December 2021 to collect dosimetric and outcomes data. All post-radiation therapy chest computed tomography (CT) scans were manually reviewed for evidence of acute (≤6 months postradiation) or chronic (>6 months postradiation) pneumonitis. RESULTS: One-hundred-ninety-one patients qualified with a median follow-up of 20.3 months (range, 5.1-42.2). Acute grade 1 (G1) pneumonitis was observed in 6.8% of the overall cohort (13 of 191 patients) and 39.4% of the patients (13 of 33) who received a chest CT ≤6 months postradiation therapy. Only 1 patient developed acute G2 pneumonitis. Chronic G1 pneumonitis was observed in 29.8% of the overall cohort (57 of 191 patients) and 77% of patients (57 of 74 patients) who received a chest CT >6 months postradiation therapy. No patients developed acute G3+ or chronic G2+ pneumonitis. CONCLUSIONS: Rates of symptomatic pneumonitis were low in this cohort of patients treated with HF-RNI, even with integration of HER2/neu-directed therapy, chemotherapy, hormone therapy, and internal mammary nodal irradiation. Lung V20Gy <26% appeared safe in this cohort to limit symptomatic pneumonitis, though this is not meant to represent the safe upper limit. Given the low event rate of symptomatic pneumonitis, data from larger cohorts will be needed to assess dosimetric predictors and the safe upper limit of lung dose.
引用
- Schad MD, Richman AH, Diego EJ, et al. Dosimetry and Toxicity Outcomes in Patients Treated with Hypofractionated Regional Nodal Irradiation for Breast Cancer: What is the Best Dose-Volume Limit to Minimize Risks of Radiation Pneumonitis? Pract Radiat Oncol. 2022. PMID: 36332799. doi:10.1016/j.prro.2022.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。